Lyka Labs Ltd

LYKALABS05 Dec 2024

Pharmaceuticals

₹

+1.50 (+0.91%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Lyka Labs Ltd

Lyka Labs Ltd

Pharmaceuticals

LYKALABS05 Dec 2024

₹

+1.50 (+0.91%)

OverviewFundamentals

Corporate action

Peer comparison

Cash flow

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
22-Oct-2024	BC	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve As per attachment. (As Per BSE Announcement	12-Nov-2024
12-Nov-2024	BC	As per attachment	12-Nov-2024
04-Oct-2024	BC	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2024 inter alia to consider and approve As per attachment As per attachment (As Pe	11-Oct-2024
09-Aug-2024	BC	The Company has accept the Resignation of Mr. Kishore P. Shah Company Secretary and Compliance Officer of the Company.	18-Sep-2024
22-Aug-2024	BC	Trading members of the Exchange are hereby informed that the under mentioned new securities of Lyka Labs Ltd. (Scrip Code - 500259) are listed and permitted to trade on the Exchange with effect from	23-Aug-2024

No Rights has been declared by LYKALABS

Book Closure

Record Date	Split Date	Purpose
12-Nov-2024	-	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve As per attachment. (As Per BSE Announcement
12-Nov-2024	-	As per attachment
11-Oct-2024	-	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2024 inter alia to consider and approve As per attachment As per attachment (As Pe
18-Sep-2024	-	The Company has accept the Resignation of Mr. Kishore P. Shah Company Secretary and Compliance Officer of the Company.
23-Aug-2024	-	Trading members of the Exchange are hereby informed that the under mentioned new securities of Lyka Labs Ltd. (Scrip Code - 500259) are listed and permitted to trade on the Exchange with effect from

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Lyka Labs Ltd ₹166.50(+1.50/0.91%)	166.50	+1.50	594.24	37.38	150.00	4.54
Ambalal Sarabhai Enterprises Ltd ₹57.99(+0.26/0.45%)	57.99	+0.26	444.40	44.98	50.43	9.86
Astrazeneca Pharma India Ltd ₹6,630.55(-30.25/-0.45%)	6,630.55	-30.25	16,576.38	37.17	128.77	24.40
Abbott India Ltd ₹29,023.75(+185.65/0.64%)	29,023.75	+185.65	61,675.47	25.54	48.01	17.52
Amrutanjan Health Care Ltd ₹738.00(-0.80/-0.11%)	738.00	-0.80	2,133.60	23.31	44.89	7.16
Bliss GVS Pharma Ltd ₹160.80(0.00/0.00%)	160.80	+0.00	1,693.74	12.68	20.96	1.65

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Cash and Cash Equivalents at Beginning of the year	8.70	15.38	6.53	8.40	0.12
Net Cash from Operating Activities	3.09	6.87	76.53	5.75	-11.45
Net Cash Used In Investing Activities	-8.61	6.77	-4.33	0.13	0.13
Net Cash Used In Financing Activities	2.71	-20.33	-63.35	-7.75	19.61
Net Inc./Dec In Cash And Cash Equivalents	-2.81	-6.69	8.85	-1.88	8.28
Cash And Cash Equivalents At End Of The Year	5.89	8.70	15.38	6.53	8.40

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

58.10%

FII Shareholding

0.15%

DII Shareholding

0.67%

Public Shareholding

41.08%

**Promoter pledged shareholding 58.10%

About Lyka Labs Ltd

Lyka Labs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 594.24 crores. It has reported a sales of Rs. 41.16 crores and a net profit of Rs. 2.47 crores for the quarter ended December 2018. The company management includes Babulal Jain, KUNAL NARENDRA GANDHI,Yogesh B Shah,Dhara P. Shah,Babulal Jain,Prashant Godha,Shashil Mendonsa,Shekhar R Singh (Lyka Labs Ltd) among others.

Chairman

Babulal Jain

Registered office

4801/B & 4802/A,GIDC Industrial Estate,Ankleshwar,Gujarat,393002

FAX :91-02646-250692

Background

Incorporation Year1976

Face Value₹10

Market Lot1